フルメキン

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H302：飲み込むと有害

  H315：皮膚刺激

  H319：強い眼刺激

  H335：呼吸器への刺激のおそれ

• 注意書き

  P261：粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。

  P305+P351+P338：眼に入った場合：水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。

フルメキン 価格

MSDS Information

• 9-Fluoro-6,7-dihydro-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylic acid

フルメキン 化学特性,用途語,生産方法

• 外観

  白色, 結晶性粉末〜粉末

• 溶解性

  アセトンに溶け、水及びエタノールにほとんど溶けない。

• 効能

  抗菌薬 (獣医薬), 核酸合成阻害薬

• 説明

  Flumequine is a synthetic antibiotic belonging to the second-generation quinolone group and is mainly active against Gram negative bacteria. It is currently the only non-humans shared broad-spectrum antimicrobial veterinary drug. It is taken as the substitute product of norfloxacin. It has a strong bactericidal activity with excellent efficacy in the treatment of animal bacterial diseases. Its main effect is to inhibit bacterial deoxy nucleic acid (DNA) gyrase, interfering with the deoxyribonucleic acid (DNA) synthesis, thereby causing failure of cell for further division, and thus playing the role of killing bacteria. It is used in bovine, ovine, chicken, rabbits, goats, horses and salmonidae, however the establishment of MRLs was only requested for non-lactating cattle, pigs, sheep, chicken and salmonidae.

• 化学的特性

  White Crystalline Solid

• 使用

  Flumequine is a fluoroquinolone compound with antimicrobial activity against Gram-negative organisms. It is used in the treatment of enteric infections in food animals and in the treatment of bacterial infections in farmed fish. Flumequine is replacing oxolinic acid in aquaculture because of its more appropriate pharmacokinetic profile and lower effective doses (Treves-Brown 2000). Flumequine also has limited use in humans for the treatment of urinary tract infections.

• 応用例（製薬）

  A tricyclic fluorinated 4-quinolone, with activity similar to that of nalidixic acid in vitro, although it is somewhat more active against some Enterobacteriaceae.
  Following escalating oral doses of 400, 800 or 1200 mg, mean peak plasma levels reached at 2 h are 13.5, 23.8 and 31.9 mg/L, respectively. The apparent elimination half-life is about 7 h. The main metabolite, hydroxyflumequine, is much more rapidly eliminated. About 60% of a dose appears in the urine, mostly in the form of conjugates. Urinary concentrations following an 800 mg dose are 10–35 mg/L, with a peak of 105 mg/L. It has no effect on the pharmacokinetics of theophylline.
  Flumequine is generally well tolerated, side effects being mainly mild gastrointestinal tract disturbances, rashes, dizziness and confusion.
  It is principally used in uncomplicated urinary tract infections.

フルメキン 上流と下流の製品情報

フルメキン 生産企業

Global(416)Suppliers

フルメキン スペクトルデータ(MS)

42835-25-6, フルメキン キーワード